大剂量沐舒坦治疗重度急性呼吸窘迫综合征的疗效观察

摘要

目的：研究大剂量沐舒坦对重度急性呼吸窘迫综合征（ARDS）患者的疗效。方法：根据2012ARDS 柏林标准选择重度 ARDS 患者40例，随机分成对照组（20例）和试验组（20例）。两组患者常规治疗的同时，对照组每天给予生理盐水20 ml 静脉推注，每6小时一次，试验组每天给予生理盐水20 ml 加沐舒坦150 mg 静脉推注，每6小时一次，连续应用7 d。比较两组患者在治疗7 d前后 APACHEⅡ评分、肺顺应性、氧合指数及 ICU 停留时间的差异。结果：与对照组相比，试验组患者7 d 后的 APACHEⅡ评分、氧合指数、肺顺应性有明显改善，ICU 停留时间缩短，两组差异有统计学意义（P ＜0.05）。结论：大剂量沐舒坦可以改善重度 ARDS 患者肺顺应性，提高氧合指数，缩短 ICU 住院时间。%Objective To study the effect of high dose Ambroxol on patients with the severe acute respiratory distress syndrome(ARDS). Method According to 2012 Berlin diagnostic criteria of ARDS,40 cases patients with severe ARDS were randomly divided into control group (20 cases)and test group(20 cases). Beside the two groups of patients were under the conventional treatment,control group received 0. 9%NaCl 20 ml Q 6 h for 7 d and the test group was given 0. 9% NaCl 20 ml and Ambroxol 150 mg Q 6 h for 7d. Compared between the two groups with APACHEⅡscore,lung compliance,oxygenation index and the ICU stay time before and after the treatment. Results Relative to the control group,APACHEⅡscore,the oxygen index and pulmonary compliance of the test group had improved significantly after 7 d,the ICU stay time was shorten,the difference was statistically significant(P <0. 05). Conclusion The application of large dose ambroxol can improve severe ARDS patients with pulmonary compliance,improve oxygenation,shorten the ICU stay time.